Clinical Trial Update: Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVD [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update evaluating Lp(a) lowering with pelacarsen (TQJ230) plus background inclisiran in participants with elevated Lp(a) and established …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atherosclerotic Cardiovascular Disease

Drugs mentioned

• Inclisiran (inclisiran)
• Pelacarsen (pelacarsen)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Atherosclerotic Cardiovascular Disease (ASCVD) | Phase 3 | Status: RECRUITING